Chief Technology Officer

Eduardo Paredes is our Chief Technology Officer. He has extensive experience in all aspects of CMC operations and project management, process/analytical development, control strategy and validation, and CMC regulatory filings. Previously, Eduardo led Process Innovation, Process Transfer and Process Development at Nitto Denko Avecia. Eduardo has been in the oligonucleotide field for over a decade in many facets including basic research, CMO operations and now drug development. He holds a Ph.D., M.S, and B.S in Chemistry from the Center for Nucleic Acid Science and Technology at Carnegie Mellon University. Eduardo is originally from Mexico but has lived in the US for over 20 years.